export const mockClientReviews = [
  {
    id: 'client-1',
    compliance_id: 'COMP-2024-001',
    submitter_name: 'Sarah Johnson',
    submitter_email: 'sarah.johnson@pharmatech.com',
    submitter_company: 'PharmaTech Solutions',
    product_name: 'Nexafib',
    therapeutic_area: 'Cardiology',
    stage: 'Launch',
    priority_level: 'High' as const,
    raw_input_content: 'Nexafib is a novel fibrate therapy...',
    ai_output: 'SEO Strategy: Focus on long-tail keywords targeting cardiologists and primary care physicians. Content pillars include mechanism of action, clinical trial data, and patient selection criteria. Estimated organic traffic increase: 150-200% within 6 months.',
    langchain_status: 'seo_approved',
    workflow_stage: 'Client_Review',
    langchain_retry_count: 0,
    created_at: new Date('2024-01-15').toISOString(),
    updated_at: new Date().toISOString(),
    seo_keywords: ['nexafib cardiology', 'novel fibrate therapy', 'lipid management innovation'],
    target_audience: ['Cardiologists', 'Primary Care Physicians', 'Endocrinologists'],
    medical_indication: 'Hyperlipidemia and cardiovascular risk reduction',
    dosage_form: 'Oral tablet, 100mg once daily',
    competitors: ['Fenofibrate', 'Gemfibrozil', 'Statins'],
    positioning: 'Next-generation fibrate with superior efficacy',
    key_differentiators: ['Once-daily dosing', 'Superior lipid control', 'Reduced side effects'],
    seo_reviewed_at: new Date('2024-01-16').toISOString(),
    seo_reviewed_by: 'SEO Team'
  },
  {
    id: 'client-2',
    compliance_id: 'COMP-2024-002',
    submitter_name: 'Michael Chen',
    submitter_email: 'mchen@biogeninnovations.com',
    submitter_company: 'BioGen Innovations',
    product_name: 'OncoShield Plus',
    therapeutic_area: 'Oncology',
    stage: 'Pre-Launch',
    priority_level: 'High' as const,
    raw_input_content: 'OncoShield Plus is an immunotherapy combination...',
    ai_output: 'SEO Strategy: Target oncology specialists and cancer centers. Focus on clinical efficacy data, safety profile, and patient access programs. Projected ROI: 3.5x within first year.',
    langchain_status: 'seo_approved',
    workflow_stage: 'Client_Review',
    langchain_retry_count: 0,
    created_at: new Date('2024-01-18').toISOString(),
    updated_at: new Date().toISOString(),
    seo_keywords: ['oncoshield immunotherapy', 'cancer treatment innovation', 'PD-1 inhibitor combination'],
    target_audience: ['Oncologists', 'Cancer Centers', 'Patients'],
    medical_indication: 'Advanced non-small cell lung cancer',
    dosage_form: 'IV infusion, 200mg every 3 weeks',
    competitors: ['Keytruda', 'Opdivo', 'Tecentriq'],
    positioning: 'Best-in-class combination immunotherapy',
    key_differentiators: ['Dual mechanism of action', 'Improved survival rates', 'Better tolerability profile'],
    seo_reviewed_at: new Date('2024-01-19').toISOString(),
    seo_reviewed_by: 'SEO Team'
  },
  {
    id: 'client-3',
    compliance_id: 'COMP-2024-003',
    submitter_name: 'Emily Rodriguez',
    submitter_email: 'erodriguez@neurotherapeutics.com',
    submitter_company: 'NeuroTherapeutics Inc',
    product_name: 'CogniMax',
    therapeutic_area: 'Neurology',
    stage: 'Phase III',
    priority_level: 'Medium' as const,
    raw_input_content: 'CogniMax is a breakthrough treatment for Alzheimer\'s...',
    ai_output: 'SEO Strategy: Build authority in Alzheimer\'s treatment space. Target neurologists, geriatricians, and caregivers. Content focus on mechanism of action, clinical trial results, and patient quality of life.',
    langchain_status: 'seo_approved',
    workflow_stage: 'Client_Review',
    langchain_retry_count: 0,
    created_at: new Date('2024-01-20').toISOString(),
    updated_at: new Date().toISOString(),
    seo_keywords: ['cognimax alzheimers', 'cognitive enhancement therapy', 'dementia treatment'],
    target_audience: ['Neurologists', 'Geriatricians', 'Caregivers', 'Patients'],
    medical_indication: 'Mild to moderate Alzheimer\'s disease',
    dosage_form: 'Oral solution, 10mg/5mL twice daily',
    competitors: ['Aricept', 'Namenda', 'Exelon'],
    positioning: 'First disease-modifying therapy with cognitive benefits',
    key_differentiators: ['Disease-modifying action', 'Cognitive improvement', 'Caregiver support program'],
    seo_reviewed_at: new Date('2024-01-21').toISOString(),
    seo_reviewed_by: 'SEO Team'
  }
]
